SCM
NKTR icon

Sterling Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Sterling Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6K Buy
+181
New +$13.2K ﹤0.01% 2102
2025
Q2 		– Sell
-205
Closed -$2.09K – 3345
2025
Q1 		$2.09K Sell
205
-176
-46% -$2.3K ﹤0.01% 2577
2024
Q4 		$5.32K Buy
381
+343
+903% +$6.05K ﹤0.01% 2448
2024
Q3 		$737 Buy
+38
New +$724 ﹤0.01% 2691

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's NKTR Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 181 shares worth $12.6K. The stake represents ﹤0.01% of the portfolio and ranks #2102 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in NKTR as recently as Q1 2025.

Sterling Capital Management first reported a position in NKTR in Q3 2024 and has held it in 4 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Sterling Capital Management held 181 shares of Nektar Therapeutics worth $12.6K as of Q2 2026.
  • Nektar Therapeutics was a new Sterling Capital Management position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2102 holding.
  • Sterling Capital Management first reported a position in Nektar Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.